Palvella Therapeutics (PVLA) Preferred Dividend Payments (2024)
Palvella Therapeutics (PVLA) reported Preferred Dividend Payments of -$582000.0 for Q4 2024, down 400.0% on a QoQ basis from $194000.0 in Q3 2024.
Palvella Therapeutics (PVLA) has 1 years of Preferred Dividend Payments data on file, last reported at -$582000.0 in Q4 2024.
- Quarterly Preferred Dividend Payments changed N/A year-over-year to -$582000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2025 was -$582000.0 (changed N/A YoY) and the FY2023 annual result came in at $776000.0, changed N/A from the prior year.
- Preferred Dividend Payments retreated to -$582000.0 in Q4 2024 per PVLA's latest filing, from $194000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $194000.0 in Q1 2024 and bottomed at -$582000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -582,000.00 |
| Sep 30, 2024 | 194,000.00 |
| Jun 30, 2024 | 194,000.00 |
| Mar 31, 2024 | 194,000.00 |